{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:39:59Z","timestamp":1768207199487,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Castleman disease (CD) is a rare lymphoproliferative disorder that can be associated with autoimmune manifestations. While paraneoplastic pemphigus (PNP) and myasthenia gravis (MG) have each been reported with CD, their simultaneous occurrence is extremely uncommon. Here, we describe a case of mixed-type unicentric Castleman disease (UCD) complicated by both MG and PNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns<\/jats:title>\n                    <jats:p>A 49-year-old man presented with fluctuating right eyelid ptosis, consistent with ocular MG. Several months later, he developed progressive oral erosions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses<\/jats:title>\n                    <jats:p>The patient was diagnosed with ocular myasthenia gravis (MG) based on fluctuating ptosis and a positive neostigmine test. Chest imaging revealed an anterior mediastinal mass initially suspected to be thymoma. Biopsy and immunopathology of the lips and oral mucosa confirmed PNP, with direct immunofluorescence showing intercellular IgG deposition and serological positivity for envoplakin and periplakin antibodies. After stabilization of systemic symptoms, the mediastinal mass was surgically removed, and histopathological examination confirmed mixed-type UCD. To date, only four previous cases of this triad have been reported in the literature, and the present case represents a mixed-type UCD subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The patient was treated with pyridostigmine for MG, systemic corticosteroids and supportive therapy for PNP, followed by complete surgical excision of the mediastinal mass once symptoms were controlled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Postoperatively, corticosteroid therapy was continued, resulting in near-complete resolution of oral lesions. During a 20-month follow-up period, the patient remained free of MG recurrence and showed no new PNP lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons<\/jats:title>\n                    <jats:p>This case highlights a rare and diagnostically challenging overlap of CD, MG, and PNP. Accurate recognition required integration of histopathology, immunofluorescence, and serological testing, achieved through multidisciplinary collaboration across thoracic surgery, neurology, dermatology, and pathology. Clinicians should remain vigilant for such complex presentations, as early diagnosis and coordinated management are essential to improving outcomes in rare autoimmune-associated CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1717172","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:44Z","timestamp":1768196384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The rare report of unicentric Castleman disease with concurrent myasthenia gravis and paraneoplastic pemphigus: a case report with a focused review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Zeyu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::aid-cncr2820090430>3.0.co;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195406102502308","article-title":"Case records of the massachusetts general hospital:\u00a0case no. 40231","volume":"250","author":"Castleman","year":"1954","journal-title":"N Engl J Med"},{"key":"B3","volume-title":"Classification of Haematolymphoid Tumours","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-","article-title":"Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations","volume":"29","author":"Keller","year":"1972","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e36114","DOI":"10.7759\/cureus.36114","article-title":"Paraneoplastic pemphigus mimicking pemphigus vulgaris associated with castleman disease","volume":"15","author":"Grigore","year":"2023","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(87)70064-4","article-title":"Concurrent features of cutaneous lupus erythematosus and pemphigus erythematosus following myasthenia gravis and thymoma","volume":"16","author":"Cruz","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2023.08.020","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology","volume":"91","author":"Anderson","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.013","article-title":"A systematic review of paraneoplastic pemphigus and paraneoplastic autoimmune multiorgan syndrome: Clinical features and prognostic factors","volume":"92","author":"Zou","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/odi.15158","article-title":"Oral manifestations in paraneoplastic syndromes: A systematic review and meta-analysis","volume":"31","author":"Messina","year":"2025","journal-title":"Oral Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/med-23-23","article-title":"Histopathological features of giant mediastinal tumors-a literature review","volume":"7","author":"Brcic","year":"2023","journal-title":"Mediastinum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/antib13040095","article-title":"Oral paraneoplastic pemphigus: A scoping review on pathogenetic mechanisms and histo-serological profile","volume":"13","author":"De Falco","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70111-8","article-title":"Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans","volume":"41","author":"Chorzelski","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23657","article-title":"Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome","volume":"47","author":"Jakub\u00edkov\u00e1","year":"2013","journal-title":"Muscle Nerve"},{"key":"B15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/0019-5154.135528","article-title":"Castleman\u2019s disease with paraneoplastic pemphigus","volume":"59","author":"Dinesha","year":"2014","journal-title":"Indian J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15138","article-title":"Paraneoplastic pemphigus associated with Castleman disease: A multicenter case series","volume":"40","author":"Barry","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20924","article-title":"Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity","volume":"1","author":"Brown","year":"2012","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman disease pathogenesis","volume":"32","author":"Fajgenbaum","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J\u00a0Neuroimmunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1356300","article-title":"IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model","volume":"15","author":"Miyake","year":"2024","journal-title":"Front Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2357689","article-title":"Immunology and targeted therapy in Castleman disease","volume":"20","author":"Tsunoda","year":"2024","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1717172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:45Z","timestamp":1768196385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1717172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1717172"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1717172","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1717172"}}